



April 23, 2014

**CERBA EUROPEAN LAB S.A.S. ANNOUNCES RECEIPT OF REQUISITE CONSENTS IN CONNECTION WITH THE CONSENT SOLICITATION RELATING TO ITS 7.00% SENIOR SECURED NOTES DUE 2020 AND EXECUTION OF THE SUPPLEMENTAL INDENTURE**

**Regulation S Notes: Common Code 087760707/ ISIN Number XS0877607076**

**Rule 144A Notes: Common Code 087760600/ ISIN Number XS0877606003**

SAINT-OUEN-L'AUMÔNE, France, April 23, 2014 -- Cerba European Lab S.A.S. (the "**Issuer**") today announced that it has received consents from holders of a majority in aggregate principal amount of its outstanding €365,000,000 7.00% Senior Secured Notes due 2020 (the "**Notes**") pursuant to the solicitation (the "**Solicitation**") of consents (the "**Consents**") in accordance with the consent solicitation statement (the "**Consent Solicitation Statement**"), dated as of April 11, 2014, to certain proposed amendments and waivers (the "**Proposed Amendments and Waivers**") to the indenture dated January 31, 2013 and as amended and supplemented from time to time (the "**Indenture**"), among the Issuer, Wilmington Trust, National Association, as Trustee (the "**Trustee**"), Wilmington Trust (London) Limited as Security Agent (the "**Security Agent**"), Citibank N.A., London Branch, as Paying Agent (the "**Paying Agent**") and Transfer Agent (the "**Transfer Agent**"), Citigroup Global Markets Deutschland AG, as Registrar (the "**Registrar**"), Cerberus Nightingale 1 S.à r.l. ("**Top Luxco**"), Cerberus Nightingale 2 S.A. ("**Luxco**"), Financière Gaillon 13 S.A.S. ("**Holdco**") and the other entities listed on Schedule I thereto (the "**Guarantors**") pursuant to which the Notes were issued.

As a result of the receipt of Consents from a majority in aggregate principal amount of the Notes, the Issuer, the Trustee, the Paying Agent, the Security Agent and the other applicable parties have executed a supplemental indenture (the "**Supplemental Indenture**") to the Indenture, which is effective and which implements the Proposed Amendments and Waivers. Upon the effectiveness of the Supplemental Indenture, Consents are no longer revocable. The Supplemental Indenture will become operative on the payment date specified below.

The Issuer will pay cash consideration of €1.00 for each €1,000 principal amount of Notes as soon as practicable to all holders of the Notes recorded as holding Notes as of the close of business on the business day prior to the payment date. The payment date is currently expected to be April 24, 2014.

The Issuer has retained Goldman Sachs International to act as solicitation agent and Lucid Issuer Services Limited to act as tabulation and information agent for the Solicitation. Questions regarding the Solicitation may be directed to Goldman Sachs International at +44 (0)207 774 9862. Requests for documents relating to the Solicitation may be directed to Lucid Issuer Services Limited at +44 (0)207 704 0880.

This press release is for informational purposes only and the Solicitation is being made only pursuant to the terms of the Consent Solicitation Statement. The Solicitation is not being made to, and Consents are not being solicited from, holders of Notes in any jurisdiction in which it is unlawful to make such Solicitation or grant such Consent. None of the Issuer, the Guarantors, the Trustee, the Security Agent, the Paying Agent, the solicitation agent or the information and tabulation agent or any other person makes any recommendation as to whether or not holders should deliver Consents.

### About Cerba European Lab

*The Issuer (formerly named Financière Gaillon 12) was incorporated on June 8, 2010 and acquired the company formerly named Cerba European Lab (the “Company”) on July 21, 2010. On June 27, 2012, the Company was merged into the Issuer. Subsequently, on July 2, 2012, the Issuer changed its legal name from Financière Gaillon 12 to Cerba European Lab.*

*We are a leading European clinical pathology laboratory, providing routine and specialized clinical laboratory testing services primarily in France, Belgium and Luxembourg, and supporting pharmaceutical and biotechnology companies worldwide in the clinical trial phase of their drug development processes.*

### No offer of securities

*This announcement is for information purposes only and does not constitute an offer to sell or issue or the solicitation of an offer to buy or subscribe for securities in the United States or any other jurisdiction. This announcement is not a public offering in France or an offer of securities to the public in any European Economic Area member state that has implemented directive 2003/71/EC.*

*The distribution of this announcement in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about, and to observe, any such restrictions.*

### Cautionary Statement Regarding Forward-Looking Statements

*This press release includes forward-looking statements. All statements, other than statements of historical fact, included in this press release regarding our financial condition or regarding future events or prospects are forward-looking statements. The words “aim,” “anticipate,” “believe,” “continue,” “estimate,” “expect,” “future,” “help,” “intend,” “may,” “plan,” “shall,” “should,” “will” or the negative or other variations of them as well as other statements regarding matters that are not historical fact, are or may constitute forward-looking statements. We have based these forward-looking statements on management’s current view with respect to future events and financial performance. These views reflect the best judgment of our management but involve a number of risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those predicted in our forward-looking statements and from past results, performance or achievements. All forward-looking statements contained in this press release are qualified in their entirety by this cautionary statement. We do not intend to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. All subsequent written or oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the cautionary statements contained throughout this press release. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements.*